The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial
Nutrients · 2024
DOI: 10.3390/nu16213580 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Ryuta Ejima und 17 weiteren Autor:innen. Beteiligte Einrichtung: Innovative Research Institute, Morinaga Milk Industry Co., Ltd., 1-83, 5-Chome, Higashihara, Zama 252-8583, Kanagawa, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Cultured Milk Products, Probiotics, Feces. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Probiotics, particularly those native to the gut microbiota, have a profound influence on the gut environment. In this study, we conducted a randomized placebo-controlled, double-blind, parallel-group comparison trial to investigate the effects of Bifidobacterium longum BB536 (B. longum BB536) on the fecal microbiota and metabolite compositions in healthy individuals. We compared the effects of fermented milk produced solely with Streptococcus thermophiles and Lactobacillus bulgaricus (placebo group) and fermented milk supplemented with B. longum BB536 (BY group). Our findings revealed a significantly greater relative abundance of Faecalibacterium in the BY group than in the placebo group by the 3rd day, a trend that persisted until the end of the trial on the 17th day. Additionally, the BY group presented significantly increased concentrations of tryptophan (Trp), Indole-3-lactic acid, and Indole-3-aldehyde on the 17th day. A significant positive correlation was observed between the relative abundance of Faecalibacterium and the number of viable B. longum BB536 bacteria in the feces. The concentrations of Trp and Indole-3-acetic acid were also significantly correlated with the number of viable B. longum BB536 bacteria in the feces. Our results suggest that B. longum BB536 intake can modulate the gut microbiota and metabolite profiles, which are general indicators for monitoring the gut environment, potentially conferring health benefits to the host.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovative Research Institute, Morinaga Milk Industry Co., Ltd., 1-83, 5-Chome, Higashihara, Zama 252-8583, Kanagawa, Japan.
- Food Research & Development Institute, Morinaga Milk Industry Co., Ltd., 1-83, 5-Chome, Higashihara, Zama 252-8583, Kanagawa, Japan.
- Matsumoto City Hospital, 4417-180 Hata, Matsumoto 390-1401, Nagano, Japan.
ORCID-Profile: Ryuta Ejima, Hiroki Kaneko, Natsumi Muto, Toshitaka Odamaki
Zitieren
APA
Ejima, R., Mishima, R., Sen, A., Yamaguchi, K., Mitsuyama, E., Kaneko, H., Kimura, M., Arai, S., Muto, N., Hiraku, A., Kato, K., Kuwano, Y., Maruyama, H., Nakamura, M., Iwabuchi, N., Nakano, M., Odamaki, T., & Tanaka, M. (2024). The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial. Nutrients. https://doi.org/10.3390/nu16213580
Vancouver
Ejima R, Mishima R, Sen A, Yamaguchi K, Mitsuyama E, Kaneko H, et al. The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial. Nutrients. 2024. doi:10.3390/nu16213580
BibTeX
@article{Ejima2024,
author = {Ejima, Ryuta and Mishima, Riko and Sen, Akira and Yamaguchi, Kana and Mitsuyama, Eri and Kaneko, Hiroki and Kimura, Madoka and Arai, Satoshi and Muto, Natsumi and Hiraku, Akari and Kato, Kumiko and Kuwano, Yasuyuki and Maruyama, Hiroshi and Nakamura, Masahiko and Iwabuchi, Noriyuki and Nakano, Manabu and Odamaki, Toshitaka and Tanaka, Miyuki},
title = {The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16213580}
}
EUVIMED